Manufacturing and use of human placenta-derived mesenchymal stromal cells for phase I clinical trials: establishment and evaluation of a protocol.
Ilić N., Atkinson K.
Clinical Trial on Tendon Injury, published in Vojnosanit Pregl (2014) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Vojnosanit Pregl (2014)
- Country
- Serbia
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25109112
- DOI
- 10.2298/vsp130410050i
Abstract (original English)
Mesenchymal stromal cells (MSCs) have been utilised in many clinical trials as an experimental treatment in numerous clinical settings. Bone marrow remains the traditional source tissue for MSCs but is relatively hard to access in large volumes. Alternatively, MSCs may be derived from other tissues including the placenta and adipose tissue. In an initial study no obvious differences in parameters such as cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability, were detected when we compared human marrow derived-MSCs to human placenta-derived MSCs. The aim of this study was to establish and evaluate a protocol and related processes for preparation placenta-derived MSCs for early phase clinical trials. A full-term placenta was taken after delivery of the baby as a source of MSCs. Isolation, seeding, incubation, cryopreservation of human placenta-derived MSCs and used production release criteria were in accordance with the complex regulatory requirements applicable to Code of Good Manufacturing Practice manufacturing of ex vivo expanded cells. We established and evaluated instructions for MSCs preparation protocol and gave an overview of the three clinical areas application. In the first trial, MSCs were co-transplanted iv to patient receiving an allogeneic cord blood transplant as therapy for treatment-refractory acute
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Effect of stem cell therapies on tendon-bone healing after anterior cruciate ligament reconstruction in animal models: Protocol for a systematic review and meta-analysis
Meta-analysis on Tendon Injury, Ligament Injury, Chronic Wound, published in PLoS One (2026) — summary generated from the PubMed abstract.
- 2026
PLoS One1 citations - Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Tendon healing in the era of regenerative medicine: literature review
Systematic Review on Tendon Injury, published in Ann Transl Med (2026) — summary generated from the PubMed abstract.
- 2026
Ann Transl Med - Level AMeta-analysisEurope PMC
Surgical vs. non-surgical therapy for partial tears of the rotator cuff: a systematic review and meta-analysis of pooled studies with indirect comparison
Meta-analysis with a reported sample of 818 on Tendon Injury, Rotator Cuff, Shoulder Pain, published in BMC Musculoskelet Disord (2026) — summary generated from the PubMed abstract.
- 2026
- n = 818
BMC Musculoskelet Disord - Level AMeta-analysisEurope PMC
Efficacy of stem cell therapy for achilles tendon rupture: a systematic review and meta-analysis based on animal studies
Meta-analysis on Tendon Injury, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level ASystematic ReviewEurope PMC
Treatment options for Achilles tendinopathy: a scoping review of preclinical studies
Systematic Review on Tendon Injury, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
PeerJ4 citations